Ardent Health Q4 adj EBITDA down 26.6% to $134M; 2026 guidance issued

Ardent Health, Inc.

Q4 total revenue $1.605B (flat YoY); net income $45M vs $114M prior year.
Q4 adjusted EBITDA $134M (down 26.6% YoY) due to annualization of prior-year benefits.
Full-year 2025 revenue $6.32B (+6%); adjusted EBITDA $545M (+9.3%); margin +20bps to 8.6%.
2026 guidance: revenue $6.4B-$6.7B, adjusted EBITDA $485M-$535M, reflecting headwinds.
Net leverage improved to 0.8x; operating cash flow $471M (+49% YoY); share buyback $3M in Q4.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Ardent Health, Inc. reported the quarter ended December 31, 2025 results: revenue $1,605 million, net income $45 million, EPS $0.32 per diluted share. Guidance initiated.

Period: the quarter ended December 31, 2025
Revenue: $1,605 million
Net income: $45 million
EPS: $0.32 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics. Total Revenue 4Q25 : $1.61 billion 2025 : $6.32 billion ; 6.0% growth Y/Y Net Income Attributable to Ardent Health 4Q25 : $45 million Adjusted EBITDA (1) 4Q25 : $134 million 2025 : $545 million ; 9.3% growth Y/Y

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Ardent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-014640

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.